Russia has introduced Enteromix, the world’s first cancer vaccine based on mRNA technology, showing 100% efficacy and no significant side effects in clinical trials. Developed by the National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB), Enteromix marks a major breakthrough in oncology.

Unlike traditional cancer treatments such as chemotherapy and radiation—which often result in severe side effects—Enteromix is administered via a simple intramuscular injection and selectively targets cancer cells while preserving healthy tissue.

READ MORE:

Eggs Thrown at Aleema Khan Outside Adiala Jail During Media Talk

The vaccine works by using mRNA technology to train the immune system to detect and eliminate cancer cells. Currently in early clinical use at select oncology centers in Russia, it awaits final approval from the Ministry of Health for nationwide distribution.

Enteromix could benefit patients with lung, breast, colorectal, and pancreatic cancers, including those with BRCA1/2 mutations, chemotherapy-resistant tumors, and weakened immune systems.

Experts believe Enteromix could revolutionize global cancer care, signaling a shift toward personalized and less invasive therapies.